Regeneron posts nearly $1.2 billion net income for 2017

Regeneron Pharmaceuticals reported a net income of $174 million, or $1.62 per basic share, in the fourth quarter of 2017 compared with a net income of $253 million, or $2.41 per basic share, in the fourth quarter of 2016.

For the full year, the company reported a net income of $1.199 billion, or $11.27 per basic share, compared with a net income of $896 million, or $8.55 per basic share, in 2016, according to a press release.

Fourth quarter sales of Eylea (aflibercept) in the United States increased 14% to $975 million, while full-year sales increased 11% to $3.7 billion. Global net sales of Eylea increased 19% in the quarter to $1.61 billion and 14% for the full year to $5.93 billion.

Research and development costs totaled $528 million for the quarter and $2.075 billion for the full year, compared with $479 million and $2.052 billion, respectively, the previous year.

Regeneron Pharmaceuticals reported a net income of $174 million, or $1.62 per basic share, in the fourth quarter of 2017 compared with a net income of $253 million, or $2.41 per basic share, in the fourth quarter of 2016.

For the full year, the company reported a net income of $1.199 billion, or $11.27 per basic share, compared with a net income of $896 million, or $8.55 per basic share, in 2016, according to a press release.

Fourth quarter sales of Eylea (aflibercept) in the United States increased 14% to $975 million, while full-year sales increased 11% to $3.7 billion. Global net sales of Eylea increased 19% in the quarter to $1.61 billion and 14% for the full year to $5.93 billion.

Research and development costs totaled $528 million for the quarter and $2.075 billion for the full year, compared with $479 million and $2.052 billion, respectively, the previous year.